CLYM
Climb Bio, Inc. (NASDAQ)
Healthcare — Biotechnology
Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies to address unmet needs for patients living with immune-mediated diseases. The company's lead product candidate is the budoprutug, an anti-CD19 monoclonal antibody for the treatment of B-cell mediated diseases. It is also developing budoprutug which is in phase 2 clinical trials for the treatment of primary membranous nephropathy and immune thrombocytopenia; and Phase 1b clinical trial indicated for the systemic lupus erythematosus. In addition, the company is developing CLYM116, a preclinical stage anti A Proliferation-inducing Ligand (APRIL) monoclonal antibody for the treatment of immunoglobin A nephropathy (IgAN) and other B-cell mediated diseases. The company was formerly known as Eliem Therapeutics, Inc. and changed its name to Climb Bio, Inc. in October 2024. Climb Bio, Inc. was incorporated in 2018 and is headquartered in Wellesley Hills, Massachusetts.
Price History
Fundamentals
| Market Cap | $761.03M |
| P/E Ratio (TTM) | - |
| Forward P/E | -11.84 |
| EPS (TTM) | $-0.77 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | - |
| ROE | -30.92% |
| Debt/Equity | 0.32 |
| Recommendation | Strong Buy 1.1 |
| Analyst Target | $20.93 |
| Analysts | 14 |
| Indexes | NASDAQ |
Technical Indicators
| RSI (14) | 75.6 |
| Beta | 0.10 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $13.69 |
| 52-Week Low | $1.21 |
| 50-Day Avg | $11.00 |
| 200-Day Avg | $5.92 |
| Avg Volume | $1.11M |
| Volume | $1.91M |
Performance Analysis
NEUTRALCLYM presents a mixed picture with both positive and negative indicators.
Recent News
Last updated: Jul 02, 2026 13:03 UTC
Back to Screener Export Report